

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'AGRICOLA' ENTERED AT 15:50:34 ON 15 DEC 2003

FILE 'BIOTECHNO' ENTERED AT 15:50:34 ON 15 DEC 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 15:50:34 ON 15 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 15:50:34 ON 15 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IMSDRUGCONF' ENTERED AT 15:50:34 ON 15 DEC 2003

COPYRIGHT (C) 2003 IMSWORLD Publications Ltd.

FILE 'LIFESCI' ENTERED AT 15:50:34 ON 15 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:50:34 ON 15 DEC 2003

COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'PASCAL' ENTERED AT 15:50:34 ON 15 DEC 2003

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

=> isotype matched negative control

L1	0 FILE AGRICOLA
L2	1 FILE BIOTECHNO
L3	0 FILE CONFSCI
L4	0 FILE HEALSAFE
L5	0 FILE IMSDRUGCONF
L6	1 FILE LIFESCI
L7	0 FILE MEDICONF
L8	2 FILE PASCAL

TOTAL FOR ALL FILES

L9 4 ISOTYPE MATCHED NEGATIVE CONTROL

=> dup rem

ENTER L# LIST OR (END):19  
DUPLICATE IS NOT AVAILABLE IN 'IMSDRUGCONF, MEDICONF'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L9  
L10 2 DUP REM L9 (2 DUPLICATES REMOVED)

=> d l10 ibib abs total

L10 ANSWER 1 OF 2 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED. on  
STN  
ACCESSION NUMBER: 2002-0555334 PASCAL  
COPYRIGHT NOTICE: Copyright .COPYRGT. 2002 INIST-CNRS. All rights

reserved.

TITLE (IN ENGLISH): GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions

AUTHOR: MENSCH Leon S.; WELLER Lindsay; SIMMONS-ARNOLD Linda; GIBSON Pamela C.; LEIMAN Gladwyn; BEATTY Barbara

CORPORATE SOURCE: Divisions of Experimental Pathology and Cytopathology, Department of Anatomical Pathology, Fletcher Allen Health Care and University of Vermont, Burlington, Vermont, United States

SOURCE: Acta cytologica, (2002), 46(5), 813-818, 9 refs.  
ISSN: 0001-5547 CODEN: ACYTAN

DOCUMENT TYPE: Journal

BIBLIOGRAPHIC LEVEL: Analytic

COUNTRY: United States

LANGUAGE: English

AVAILABILITY: INIST-10515, 354000109305770040

AN 2002-0555334 PASCAL

CP Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.

AB OBJECTIVE: To determine whether GLUT1 antibody could replace one or more of the currently used antiepithelial antibodies and to assess whether ThinPrep.RTM. methodology is suited to immunocytochemical (ICC) evaluation. STUDY DESIGN: In a prospective study of 10 fluids containing malignant cells from cases of proven adenocarcinoma and 10 cytologically benign effusions, multiple slides were prepared by ThinPrep.RTM. technology for staining with four commercially available antibodies and appropriate isotype-matched negative controls. The antibodies used were GLUT1, CEA, B72.3 and Leu-M1 (CD 15). Tissue sections and ThinPrep.RTM. slides were used as positive controls. Specimens were batched to ensure similar conditions for all antibody reactions. RESULTS: Of the 11 cases ultimately proven to be carcinoma, GLUT1 and B72.3 stained 7 each (63.6%), and CEA and Leu-M1 6 each (54.5%). No false positive staining was encountered, but one case chosen as a benign control was shown to contain immunopositive cells by three of the four epithelial markers used; this case was therefore an occult true positive rather than a false positive. CONCLUSION: In this small but controlled prospective analysis, GLUT1 demonstrated strong positive staining, with sensitivity similar to that of currently used epithelial markers. Using GLUT1 in conjunction with B72.3, no cases of carcinoma were missed. GLUT1 could be used in a panel of antibodies designed to confirm the presence of adenocarcinoma. ThinPrep.RTM. methodology, which enables multiple slides to be prepared after routine microscopy determines the need for ICC, appears suited to this adjuvant investigation.

L10 ANSWER 2 OF 2 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN  
DUPLICATE

ACCESSION NUMBER: 2000:30734596 BIOTECHNO

TITLE: Intracellular markers

AUTHOR: Koester S.K.; Bolton W.E.

CORPORATE SOURCE: W.E. Bolton, Beckman Coulter, Inc., Advanced Technology, M/C 22-A01, 11800 S.W. 147th Avenue, Miami, FL 33196-2500, United States.  
E-mail: wadeb4@aol.com

SOURCE: Journal of Immunological Methods, (21 SEP 2000), 243/1-2 (99-106), 54 reference(s)  
CODEN: JIMMBG ISSN: 0022-1759

PUBLISHER ITEM IDENT.: S0022175900002398

DOCUMENT TYPE: Journal; General Review

COUNTRY: Netherlands

LANGUAGE: English

SUMMARY LANGUAGE: English

AN 2000:30734596 BIOTECHNO

AB An increased level of complexity will be encountered when developing protocols for intracellular markers. Protocols for surface markers have

been successfully standardized, however it is understood that no single method is appropriate for all intracellular staining. A systematic approach should be followed, including knowledge of antigen location and functional state, selection of cell fixative and cell permeabilizer, antibody specificity and class/subclass, fluorochrome, fluorochrome to protein ratio (F:P), and use of adequate controls, including **isotype-matched negative controls** and positive and negative cell controls. Even though it is impossible to recommend a single technique to stain all intracellular antigens, the authors present a logical approach to follow when developing a staining protocol. (C) 2000 Elsevier Science B.V.

=> file .chemistry  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.13	9.34

FILE 'CAPLUS' ENTERED AT 15:52:12 ON 15 DEC 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 15:52:12 ON 15 DEC 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 15:52:12 ON 15 DEC 2003  
Compendex Compilation and Indexing (C) 2003  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 15:52:12 ON 15 DEC 2003  
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 15:52:12 ON 15 DEC 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 15:52:12 ON 15 DEC 2003  
COPYRIGHT (c) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 15:52:12 ON 15 DEC 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> isotype matched negative control  
L11 2 FILE CAPLUS  
L12 1 FILE BIOTECHNO  
L13 0 FILE COMPENDEX  
L14 0 FILE ANABSTR  
L15 0 FILE CERAB  
L16 0 FILE METADEX  
L17 91 FILE USPATFULL

TOTAL FOR ALL FILES  
L18 94 ISOTYPE MATCHED NEGATIVE CONTROL

=> dup rem  
ENTER L# LIST OR (END) :l11-16  
L13 HAS NO ANSWERS  
L14 HAS NO ANSWERS  
L15 HAS NO ANSWERS  
L16 HAS NO ANSWERS  
PROCESSING COMPLETED FOR L11  
PROCESSING COMPLETED FOR L12  
PROCESSING COMPLETED FOR L13

PROCESSING COMPLETED FOR L14

PROCESSING COMPLETED FOR L15

PROCESSING COMPLETED FOR L16

L19 2 DUP REM L11-16 (1 DUPLICATE REMOVED)

=> d l19 ibib abs total

L19 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2000:635692 CAPLUS

DOCUMENT NUMBER: 134:28283

TITLE: Intracellular markers

AUTHOR(S): Koester, S. K.; Bolton, W. E.

CORPORATE SOURCE: Advanced Technology, Beckman Coulter, Inc., Miami, FL,  
33196-2500, USA

SOURCE: Journal of Immunological Methods (2000), 243(1-2),  
99-106

CODEN: JIMMBG; ISSN: 0022-1759

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with numerous refs. An increased level of complexity will be encountered when developing protocols for intracellular markers. Protocols for surface markers have been successfully standardized, however it is understood that no single method is appropriate for all intracellular staining. A systematic approach should be followed, including knowledge of antigen location and functional state, selection of cell fixative and cell permeabilizer, antibody specificity and class/subclass, fluorochrome, fluorochrome to protein ratio (F:P), and use of adequate controls, including **isotype-matched neg. controls** and pos. and neg. cell controls. Even though it is impossible to recommend a single technique to stain all intracellular antigens, the authors present a logical approach to follow when developing a staining protocol.

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:93649 CAPLUS

DOCUMENT NUMBER: 118:93649

TITLE: In vitro tumor toxicity with antibody-toxin conjugates

AUTHOR(S): May, Richard D.; Fulton, R. Jerrold

CORPORATE SOURCE: Chemotherapy Toxicol. Dep., South. Res. Inst.,  
Birmingham, AL, USA

SOURCE: In Vitro Methods Toxicol. (1992), 9-20. Editor(s):  
Watson, Ronald Ross. CRC: Boca Raton, Fla.

CODEN: 58SAA7

DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

AB A review with 79 refs. in how to prep. and test immunotoxins (ITs) for killing tumor cells in vitro. The section of toxin and Ab are crucial for constructing a successful IT. The authors have provided detailed methodol. for constructing an IT-A using ricin A chain, which is widely used in this field. The purity, Ab binding activity, and cytotoxic efficacy of the IT-As are tested by appropriate in vitro methods. Specificity of killing is demonstrated by a direct IT-A assay, which includes using an **isotype-matched neg. control** IT-A, as well as an Ag-neg. cell line. Careful in vitro testing of ITs can predict some of the problems assocd. with their in vivo applications, such as liver toxicity, and nonspecific binding to nontarget tissues. However, in vitro efficacy may not always be translated into in vivo usefulness. Thus, preclin. in vivo animal models must eventually be developed and tested prior to using ITs clin.

control IT-A, as well as an Ag-neg. cell line. Careful in vitro testing of ITs can predict some of the problems assocd. with their in vivo applications, such as liver toxicity, and nonspecific binding to nontarget tissues. However, in vitro efficacy may not always be translated into in vivo usefulness. Thus, preclin. in vivo animal models must eventually be developed and tested prior to using ITs clin.